logo

For the Inventor, By the Inventor

Morton Grove, IL, United States of America

Leland J Chinn

This inventor holds 11 USPTO granted patents. Top assignees: G.d. Searle & Company, G. D. Serale & Co.. Active years: 1976-1992.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Leland J Chinn. Retrieved from https://idiyas.com/inventor/leland-j-chinn

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11

% Patents Active = 100.0

Average Co-Inventor Count = 1.8

ph-index = 4

Forward Citations = 57(Granted Patents)


Location History:

  • Morton Grove, IL (US) (1976 - 1983)
  • Glenview, IL (US) (1984 - 1987)
  • Montebello, CA (US) (1989 - 1992)

Company Filing History:

goldMedal10 out of 1,323 
 
G.d. Searle & Company
 patents
silverMedal1 out of 1 
 
G. D. Serale & Co.
 patent

Years Active: 1976-1992

Loading Chart...
11 patents (USPTO):Explore Patents
1. 5162365 - 5-lipoxygenase inhibitors (1992-11-10),
2. 5036105 - 5-lipoxygenase inhibitors (1991-07-30),
3. 4801611 - 5-lipoxygenase inhibitors (1989-01-31),
4. 4694018 - Substituted 1,5-diphenyl-2-pyrrolepropionic acids and derivatives (1987-09-15),
5. 4687864 - 5-fluoro-3-oxa-prostacyclin compounds (1987-08-18),
6. 4579958 - 5-fluoro-3-oxa-6,7-didehydro-PGI.sub.1 compounds (1986-04-01),
7. 4459235 - 2-Cyanosteroids (1984-07-10),
8. 4388311 - Method for the induction of menses (1983-06-14),
9. 4349474 - 2-Cyanosteroids (1982-09-14),
10. 4010169 - (E)-4-Hydroxy-11,15-dioxoprosta-8(12),13-dien-1-oic acid .gamma.-lactones (1977-03-01),
11. 3954844 - (5Z,13E,15S)-15-Hydroxy-11-oxoprosta-5,9.13-trien-1-oic acid and esters (1976-05-04),

Title: Leland J Chinn: Innovator in Pharmaceutical Advancements

Introduction: Leland J Chinn is a notable inventor based in Morton Grove, Illinois, recognized for his contributions to the field of pharmaceuticals. With a remarkable portfolio of 11 patents, his work has significantly impacted the development of treatments targeting inflammation and allergy.

Latest Patents: Among his latest innovations, Chinn has developed a series of 5-lipoxygenase inhibitors. These inventions encompass compounds and methods aimed at inhibiting lipoxygenase, particularly beneficial in formulating pharmaceutical compositions. One notable formulation includes a pharmaceutical carrier combined with an effective lipoxygenase inhibiting amount of a specific compound formula. The invention targets disorders influenced by the 5-lipoxygenase metabolic pathway, proving its utility in managing local and systemic inflammation, as well as allergy and hypersensitivity reactions.

Career Highlights: Chinn's professional journey includes significant roles at reputable companies such as G.D. Searle & Company. His work in these organizations has been pivotal in translating scientific research into pharmaceutical applications, showcasing the practical implications of his innovations.

Collaborations: Throughout his career, Leland has collaborated with esteemed colleagues including Bipinchandra N Desai and Richard A Mueller. These partnerships have contributed to the advancement of his research and the successful development of his patents.

Conclusion: Leland J Chinn stands out as a prolific inventor whose contributions have enhanced therapeutic options for various medical conditions. His dedication to innovation within the pharmaceutical sector continues to pave the way for future advancements in healthcare.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…